Literature DB >> 8710881

Mammalian cells resistant to tumor suppressor genes.

J A Pietenpol1, C Lengauer, J Jordan, K W Kinzler, B Vogelstein.   

Abstract

Expression of p53 causes growth arrest or apoptosis in many normal and neoplastic cell types, but the relationship between these two effects has remained obscure. To begin to dissect the underlying mechanisms at a genetic level, we have generated mutant cells resistant to the action of wild-type p53. Rat embryo fibroblasts transformed with ras and a temperature-sensitive p53 (tsp53(135val)) gene were chemically mutagenized and selected for growth at a temperature at which p53 adopts a wild-type conformation (31.5 degrees C). Clones that grew exponentially at 31.5 degrees C were selected. Cell fusion experiments demonstrated that the mutations conferring resistance to p53-mediated growth arrest were dominant. The mutagenized clones were resistant not only to p53-mediated growth arrest, but also to the apoptosis induced by E1A in conjunction with p53, and partially resistant to the retinoblastoma tumor suppressor, pRB. The results suggest that a single downstream pathway can control the induction of growth arrest and apoptosis, and that both p53 and RB function through this pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710881      PMCID: PMC38681          DOI: 10.1073/pnas.93.16.8390

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

2.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

3.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.

Authors:  M Debbas; E White
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

4.  Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents.

Authors:  J Lotem; L Sachs
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

5.  Death-defying acts: a meeting review on apoptosis.

Authors:  E White
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

6.  Sequence-specific transcriptional activation is essential for growth suppression by p53.

Authors:  J A Pietenpol; T Tokino; S Thiagalingam; W S el-Deiry; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

7.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

8.  Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.

Authors:  S W Lowe; H E Ruley
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

9.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 10.  Bcl-2 and the regulation of programmed cell death.

Authors:  J C Reed
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

View more
  3 in total

1.  Use of the two-hybrid system to identify protein-protein interaction temperature-sensitive mutants: application to the CDK2/p21Cip1 interaction.

Authors:  C Cayrol; G Cabrolier; B Ducommun
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

2.  Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.

Authors:  M H Aziz; H Shen; C G Maki
Journal:  Oncogene       Date:  2011-06-06       Impact factor: 9.867

Review 3.  Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.

Authors:  P S Obermiller; D L Tait; J T Holt
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.